Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

CDK

Cyclin-dependent kinases (CDKs) are the families of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells.They are present in all known eukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved.

  • Dinaciclib
    T1912779353-01-4
    Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). Dinaciclib has potential antitumor activity and inhibits the incorporation of thoracic glycan (dThd) DNA.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Ribociclib
    T61991211441-98-3
    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50:10/39 nM).
    • $36
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • AS2863619
    T83782241300-51-4
    AS2863619 is an orally active inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19 (IC50s of 0.61 nM and 4.28 nM, respectively).
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • PF07104091
    T97122460249-19-6
    PF07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
    • $372
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • SY-5609
    T360382417302-07-7In house
    SY-5609 is a selective and noncovalent inhibitor of CDK7(KD = 0.065 nM) with antitumor activity and inhibits apoptosis.
    • $142
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Abemaciclib
    T23811231929-97-7
    Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Palbociclib
    T1785571190-30-2
    Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • TAK-901
    T2709934541-31-8
    TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • NU2058
    T3186161058-83-9
    NU2058 (O(6)-Cyclohexylmethylguanine) is a guanine-based CDK inhibitor, also inhibits DNA topoisomerase II ATPase activity.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • P18IN011
    T857677408-67-4
    P18IN011 (P18IN011 - CAS 77408-67-4 - Calbiochem) is a novel inhibitor of p18(INK4C).
    • $133
    In Stock
    Size
    QTY
  • SEL120-34A
    T107441609522-33-9In house
    SEL120-34A is a selective and ATP-competitive inhibitor of CDK8 with IC50s of 4.4 nM, 10.4 nM and 1070 nM for CDK8/CycC, CDK19/CycC and CDK9/cycT. SEL120-34A possesses antitumor activity.
    • $96
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • CDK-IN-10
    T60869660822-84-4
    CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • A-674563 2HCl(552325-73-2(fb-2hcl))
    T6139L
    A-674563 2HCl is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
    • $78
    In Stock
    Size
    QTY
  • NSC23005
    T35906314-70-1
    NSC23005 sodium is a p18INK inhibitor with potently promoted hematopoietic stem cell (HSC) expansion (ED50: 5.21 nM).
    • $35
    In Stock
    Size
    QTY
  • PHA-767491
    T6206845714-00-3
    PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Cdk5 Substrate acetate
    T37207L
    Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of proteins, including histone H1 and tau. Cdk5 Substrate acetate is a synthetic peptide (PKTPKKAKKL) corresponding to a sequence of histone H1. It is phosphorylated by Cdk5 with a Km value of 5 µM.
    • $148
    In Stock
    Size
    QTY
  • MBM-55S
    T119612083624-07-9In house
    MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
    • $195
    In Stock
    Size
    QTY
  • H1k
    T72057 In house
    H1k is an eudistomin Y fluorescent derivative and lysosome-targeted antiproliferative agent that dose-dependently increases autophagy signalling and down-regulates the expression of cyclin-dependent kinase (CDK1) and cyclin B1.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • WAY-322243
    T77619332939-32-9
    WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • A-674563 HCl (552325-73-2(free base))
    T44442070009-66-2
    A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) [1]. It exhibits inhibitory activity against PKA and Cdk2 (IC50: 16 46 nM) but is 10- to >1, 800-fold selective for Akt1 versus additional kinases in th
    • $77
    In Stock
    Size
    QTY
  • DSS30
    T61439883027-32-5In house
    DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.
    • $350
    In Stock
    Size
    QTY
  • A09-003
    T794042911646-14-3In house
    A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.A09-003 also induces apoptosis, decreases RNA polymerase II activity, and decreases Mcl-1 expression.
    • $293 TargetMol
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • ML 315
    T367071440251-53-5
    ML 315 is a selective Clk and DYRK inhibitor with potential anticancer activity for the study of neurological disorders.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BUR1
    T2384023000-46-6
    BUR1 is a selective BMP upregulator that acts by increasing the expression of Inhibitor of DNA binding 1 and inducing BMP2 and PTGS2 expression.
    • $148
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • WAY-647802
    T9971852225-20-8
    WAY-647802 is a CDK inhibitor.
    • $56
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 9-Isopropylolomoucine
    T23589158982-15-1In house
    9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CLK1/2-IN-3
    T238971005784-60-0In house
    CLK1 2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1 2-IN-3 induces nuclear speckle enlargement, which induces S6K pre-mRNA-selective splicing and subsequent inhibition of cell growth of multiple cancer cell types. cancer cell types cell growth.
    • $350
    In Stock
    Size
    QTY
  • GSK-3 inhibitor 4
    T773412227279-83-4In house
    GSK-3 inhibitor 4 is an orally active and brain-permeable triple inhibitor of GSK-3, CDK2 and CDK5 with inhibitory effects on GSK-3β, GSK-3α, CDK2 and CDK5, with IC50 values of 0.56 nM, 0.45 nM, 0.47 μM, 0.68 μM, respectively.GSK-3 inhibitor 4 can effectively reduce Tau protein levels. GSK-3 inhibitor 4 can effectively reduce the level of Tau protein.GSK-3 inhibitor 4 can be used in the study of Alzheimer's disease.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Aloisine B
    T69188496864-14-3In house
    Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively. Aloisine B has antiviral activity and can be used to study Alzheimer's, diabetes, HIV and Parkinson's.
    • $350
    In Stock
    Size
    QTY
  • LDC-4297 HCl (1453834-21-3(free base))
    T4417
    LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.
    • $54
    In Stock
    Size
    QTY
  • (S)-Enitociclib
    T703881610408-97-3In house
    (S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
    • $518
    In Stock
    Size
    QTY
  • CDK4/6/1 Inhibitor
    T107352099128-41-1In house
    CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.
    • $329
    In Stock
    Size
    QTY
  • Cdk1/2 Inhibitor III
    T14914443798-55-8In house
    Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.
    • $350
    In Stock
    Size
    QTY
  • Cdc7-IN-7
    T107291402059-17-9
    Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
    • $117
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • InhA-IN-2
    T97342428737-43-1
    InhA-IN-2 directly inhibits InhA and does not require activation by the catalase peroxidase KatG.
    • $148
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • GW297361
    T75163388627-21-2
    GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 and Pho85 were 20 nM and 400 nM, respectively.
    • $247
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AZA197
    T251251249398-09-1In house
    AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.
    • $197
    In Stock
    Size
    QTY
  • SU-9516
    T8819666837-93-0
    SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
    • $92
    In Stock
    Size
    QTY
  • XL413
    T33521169558-38-6In house
    XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induct
    • $48
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • (R)-Enitociclib
    T70388L1610408-96-2In house
    (R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CDK8-IN-12
    T720482613307-67-6In house
    CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells.
    • $79
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Cdc7-IN-7c
    T238671330781-04-8In house
    Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SB1317 hydrochloride (1204918-72-8(free base))
    T4227
    SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2 JAK2 FLT3 (IC50: 13 73 56 nM).
    • $45
    In Stock
    Size
    QTY
  • SEL120-34A HCl
    T10744L1609452-30-3In house
    SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), with antitumor activity.
    • $54
    In Stock
    Size
    QTY
  • LRRK2 inhibitor 1
    T118781802525-61-6In house
    LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
    • $68
    In Stock
    Size
    QTY
  • CDK9-IN-2
    T149181263369-28-3In house
    CDK9-IN-2 is a special CDK9 inhibitor and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple myeloma cell line (72 hours), respectively.
    • $80
    In Stock
    Size
    QTY
  • NVP-LCQ195
    TQ0068902156-99-4In house
    NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
    • $67
    In Stock
    Size
    QTY
  • CDK9-IN-10
    T107423542-63-0In house
    CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
    • $45
    In Stock
    Size
    QTY
  • GP-82996
    T21720359886-84-3In house
    GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].
    • $48
    In Stock
    Size
    QTY
  • CDK9-IN-8
    T107462105956-51-0In house
    CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).
    • $53
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale